In Silico Modeling of FDA-Approved Drugs for Discovery of Anticancer Agents: A Drug-Repurposing Approach

Mengzhu Zheng; Lixia Chen; Li Hua

doi:10.1016/b978-0-12-816125-8.00017-1

ScienceGate Book Chapters

BOOK-CHAPTER

In Silico Modeling of FDA-Approved Drugs for Discovery of Anticancer Agents: A Drug-Repurposing Approach

Mengzhu Zheng Lixia Chen Li Hua

Year: 2019 Elsevier eBooks Pages: 527-548 Publisher: Elsevier BV

DOI: 10.1016/b978-0-12-816125-8.00017-1

Get Full-Text PDF Get Analytical Report

Keywords:

Drug repositioning Virtual screening Repurposing Drug In silico Drug discovery Medicine Pharmacology Drug development Computational biology Bioinformatics Biology

Metrics

Cited By

0.48

FWCI (Field Weighted Citation Impact)

116

Refs

0.57

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Citation History

Topics

Computational Drug Discovery Methods

Physical Sciences → Computer Science → Computational Theory and Mathematics

Protein Degradation and Inhibitors

Life Sciences → Biochemistry, Genetics and Molecular Biology → Molecular Biology

Click Chemistry and Applications

Physical Sciences → Chemistry → Organic Chemistry

In Silico Modeling of FDA-Approved Drugs for Discovery of Anticancer Agents: A Drug-Repurposing Approach

Metrics

Citation History

Topics

Related Documents

In Silico Modeling of FDA-Approved Drugs for Discovery of Anticandida Agents: A Drug-Repurposing Approach

In Silico Modeling of FDA-Approved Drugs for Discovery of Anti-Cancer Agents: A Drug-Repurposing Approach

In Silico Modeling of FDA-Approved Drugs for Discovery of Therapies Against Neglected Diseases: A Drug Repurposing Approach

In Silico Drug Repurposing Approach: Investigation of Mycobacterium tuberculosis FadD32 Targeted by FDA-Approved Drugs

Repurposing of FDA Approved Drugs and Neuropep peptides as Anticancer Agents Against ErbB1 and ErbB2